Circulating plasma microRNAs as potential markers to identify EGFR mutation status and to monitor epidermal growth factor receptor-tyrosine kinase inhibitor treatment in patients with advanced non-small cell lung cancer
Metrics: PDF 1943 views | HTML 2751 views | ?
Lili Qu1,*, Liangliang Li1,*, Xiaofei Zheng2, Hanjiang Fu2, Chuanhao Tang3, Haifeng Qin1, Xiaoyan Li1, Hong Wang1, Jianjie Li4, Weixia Wang1, Shaoxing Yang1, Lin Wang1, Guanhua Zhao1, Panpan Lv1, Yangyang Lei1, Min Zhang1, Hongjun Gao1, Santai Song5 and Xiaoqing Liu1
1Department of Lung Cancer, Affiliated Hospital of the Academy of Military Medical Science, Beijing, China
2Institute of Radiation Medicine, Academy of Military Medical Science, Beijing, China
3Department of Oncology, Peking University International Hospital, Beijing, China
4Department of Medical Oncology, Beijing Cancer Hospital, Beijing, China
5Department of Breast Cancer, Affiliated Hospital of the Academy of Military Medical Science, Beijing, China
*These authors have contributed equally to this work
Xiaoqing Liu, email: [email protected]
Keywords: circulating microRNA, EGFR mutation status, epidermal growth factor receptor-tyrosine kinase inhibitor, non-small cell lung cancer, tumor marker
Received: January 17, 2017 Accepted: March 17, 2017 Published: April 25, 2017
We aimed to identify a panel of circulating plasma microRNAs that can predict EGFR mutation status and monitor epidermal growth factor receptor-tyrosine kinase inhibitor treatment in patients with non-small cell lung cancer. Microarrays were performed for the preliminary screening of dysregulated microRNAs in 9 EGFR mutation-positive patients versus healthy controls. MiR-107 was upregulated and miR-195 was downregulated in the exon 19 deletion versus wild-type group. The areas under the receiver operating characteristic curves for miR-107, miR-195, and a panel of these 2 microRNAs were 0.72, 0.75, and 0.74, with sensitivities and specificities of 64.7% and 76.6%, 71.8% and 69.1%, and 71.7% and 78.9%, respectively. MiR-122 was significantly upregulated in the p.L858R versus wild-type group. An area under the receiver operative characteristic curve of 0.75 suggests that miR-122 might be a specific biomarker for patients with the p.L858R mutation. In addition, dynamic changes in these 3 microRNAs were also found to correlate with responses to epidermal growth factor receptor-tyrosine kinase inhibitor treatment, indicating that circulating plasma microRNAs may represent potential biomarkers for monitoring epidermal growth factor receptor-tyrosine kinase inhibitor treatment. This study demonstrates the prospective application of circulating plasma microRNAs as potential non-invasive, convenient biomarkers for patients with EGFR-sensitive mutations.
All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.